Obeziteyle İlişkili Güncel Peptitlere Yeni Yaklaşımlar

Yıl 2024, Cilt: 8 Sayı: 1, 111 - 120, 29.04.2024

Sümeyye Koç , Levent Sarıyıldız , Esma Menevşe

https://doi.org/10.46332/aemj.1215675

Öz

Özellikle çocukluk ve adölesan zamanlarında gelişen obezite, her yaşta önemli bir sağlık sorunu olarak karşımıza çıkmaktadır. Hipotalamusu vücudun enerji depoları hakkında uyaran hormonlar, yemek yemeyi engelleyip vücut ağırlığının belli fizyolojik sınırlar içerisinde kalmasını sağlamaktadırlar. Obezite ve obeziteyle ilişkili olan hormonların araştırılması bu kapsamda çok önemlidir. Obezite ile ilişkili hormonların günümüze kadar tespit edilmiş olan fonksiyonlarının, daha ileri çalışmalara rehberlik edebileceğini düşünmekteyiz. Bu derlemede obeziteyle ilişkili hormonlar ve onların etki mekanizmalarına değinilmiştir.

Anahtar Kelimeler

ghrelin, irisin, leptin, nesfatin-1, nöropeptid-y, oreksin

New Perspectives on Obesity Related Novel Peptides

Öz

Obesity, which develops especially in childhood and adolescence, is an important health problem at all ages. Hormones that stimulate the hypothalamus about the body's energy stores prevent eating and keep body weight within certain physiological limits. Investigating obesity and the hormones associated with obesity is very important in this context. We believe that the functions of obesity-associated hormones that have been identified to date can guide further studies. In this review, obesity-related hormones and their mechanisms of action are discussed.

Anahtar Kelimeler

ghrelin, irisin, leptin, nesfatin-1, neuropeptide-y, orexin

Kaynakça

• 1. Aktaş D, Öztürk FN, Kapan Y. Adölesanlarda obezite sıklığı ve etkileyen risk faktörleri, beslenme alışkanlıklarının belirlenmesi. TAF Prev. Med. Bull. 2015;14(5):406-412.
• 2. Aysoydan E, Çakır N. Adölesanların beslenme alışkanlıkları, fiziksel aktivite düzeyleri ve vücut kitle indekslerinin değerlendirilmesi. Gulhane Med J. 2011; 53(4):264-270.
• 3. Ergül Ş, Kalkım A. Önemli bir kronik hastalık: çocukluk ve ergenlik döneminde obezite. TAF Prev. Med. Bull. 2011;10(2):223-230.
• 4. Uskun E, Öztürk M, Kişioğlu A, Kirbiyik S, Demirel R. İlköğretim öğrencilerinde obezite gelişimini etkileyen. SDÜ Tıp Fak Derg. 2005;12(2):19-25.
• 5. Hızlı H, Büyükuslu N. Yüksek yağlı diyetin açlık-tokluk metabolizmasında görevli hormonlar ve nöropeptidler üzerine etkileri. Saglik Bilim. Derg. 2018; 27(3):239-344.
• 6. Zhang F, Chen Y, Heiman M, DiMarchi R. Leptin: structure, function, and biology. Vitam. Horm. 2005;71:345-372.
• 7. Öztürk AS, Arpacı A. Obezite ve Ghrelin/Leptin ilişkisi. Mustafa Kemal univ. tıp derg. 2018;9(35): 136-151.
• 8. Yura S, Itoh H, Sagawa N. et al. Role of premature leptin surge in obesity resulting from intrauterine undernutrition. Cell metabolism. 2005;1(6):371-378.
• 9. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999; 402(6762):656-660.
• 10. McKee KK, Palyha OC, Feighner SD, et al. Molecular analysis of rat pituitary and hypothalamic growth hormone secretagogue receptors. Mol. Endocrinol. 1997; 11(4):415-423.
• 11. Schmid SM, Hallschmid M, Jauch‐chara K, Born J, Schultes B. A single night of sleep deprivation increases ghrelin levels and feelings of hunger in normal‐weight healthy men. J. Sleep Res. 2008;17(3): 331-334.
• 12. Wyss P, Stricker-Krongrad A, Brunner L, et al. The pharmacology of neuropeptide Y (NPY) receptor-mediated feeding in rats characterizes better Y5 than Y1, but not Y2 or Y4 subtypes. Regul. Pept. 1998;75:363-371.
• 13. Holzer P, Reichmann F, Farzi A. Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut–brain axis. Neuropeptides. 2012;46(6):261-274.
• 14. Ueno H, Yamaguchi H, Mizuta M, Nakazato M. The role of PYY in feeding regulation. Regul. Pept. 2008;145(1-3):12-16.
• 15. Cox HM. Neuropeptide Y receptors; antisecretory control of intestinal epithelial function. Auton. Neurosci. 2007;133(1):76-85.
• 16. Rozengurt N, Wu SV, Chen MC, Huang C, Sternini C, Rozengurt E. Colocalisation of the a subunit of gustducin with PYY and GLP-1 in L-cells of human colon. Am. J. Physiol. 2006;291(5):792-802.
• 17. Murphy KG, Bloom SR. Gut hormones and the regulation of energy homeostasis. Nature. 2006;444(7121): 854-859.
• 18. Shimizu H, Oh IS, Satoh T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006;443(7112):709-712.
• 19. İşgüzar Y, Akbulut G. Obezite ile ilgili güncel iki hormon: Nesfatin-I ve Omentin-I. Türkiye Klinikleri J Health Sci. 2019;4(1):57-61.
• 20. Gülmez C, Atakişi O. Yeni hormonlar: R-Spondin-1, Nesfatin-1 ve İrisin. Caucasian Med J. 2019;6(1):37-50.
• 21. Daisuke K, Mascroni N, Yuko M, Hiroyuki S, Udual S, Natsu Y. Nesfatin 1 neurons in paraventricular and supraoptic nuclei of the rat hypothalamus coexpress oxytocin and vasopressin anda re activated by. Endocrinology. 2008;149(3):1295-1301.
• 22. Abaci A, Catli G, Anik A, Kume T, Bober E. The relation of serum nesfatin‐1 level with metabolic and clinical parameters in obese and healthy children. Pediatr. Diabetes. 2013;14(3):189-195.
• 23. Lees G, Coyne L. The orexins: a novel family of sleep regulating neuropeptides. CACC 2004;15(1):75-77.
• 24. Mondal MS, Nakazato M, Matsukura S. Orexins (hypocretins): novel hypothalamic peptides with divergent functions. Biochem. Cell Biol. 2000;78(3): 299-305.
• 25. Nakabayashi M, Suzuki T, Takahashi K, et al. Orexin-A expression in human peripheral tissues. Mol. Cell. Endocrinol. 2003;205(1-2):43-50.
• 26. Bülbül A, Tülüceoğlu EE, Öztürk Ö, Calapoğlu NŞ, Gonca T, Calapoğlu M. Serum oreksin seviyelerinin obezite ile ilişkisi: kesitsel ilişkilendirme çalışması. SDÜ Tıp Fak Derg. 2018;9(4):37-43.
• 27. Yurtseven DG, Minbay Z, Eyigör Ö. Nesfatin-1 ve Oeksin A nöronları arasındaki etkileşimin immünohistokimyasal olarak araştırılması. UÜTFD. 2019;45(3):243-249.
• 28. Karadağ MG, Aksoy M. Yeni keşif nöropeptitlerden: Oreksin.GTD.2009;24(2):79-87.
• 29. Beck B, Richy S, Hypothalamic hypocretin/orexin, and neuropeptide Y: divergent interaction with energy depletion and leptin. Biochem. Biophys. Res. Commun. 1999;258(1):119-122.
• 30. Pontus B, Jun W, Mark PJ at all. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012:481(7382): 463-810.
• 31. Sarioğlu B. İrisin hormonu. Sağlık ve Toplum. 2021; 31(3):59-66.
• 32. Aydın SF. Three new players in energy regulation: preptin, adropin and irisin. Peptides. 2014;56:94-110.
• 33. Crujeiras AB, Zulet MA, Lopez LP, et al. Association between circulating irisin levels and the promotion of insulin resistance during the weight maintenance period after a dietary weight-lowering program in obese patients. Metabolism. 2014;63(4):520-531.
• 34. Martinez Munoz IY, Camarillo Romero EdS, Garduno Garcia JdJ. Irisin a novel metabolic biomarker: present knowledge and future directions. Int. J. Endocrinol. 2018:7816806.
• 35. Huh JY, Mougios V, Skraparlis A, Kabasakalis A, Mantzoros CS. Irisin in response to acute and chronic whole-body vibration exercise in humans. Metabolism. 2014;63(7):918-921.
• 36. Boström P, Wu J, Jedrychowski MP, et al. A PGC1- - dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012; 481(7382):463-468.
• 37. Montez JM, Soukas A, Asilmaz E, Fayzikhodjaeva G, Fantuzzi G, Friedman JM. Acute leptin deficiency, leptin resistance, and the physiologic response to leptin withdrawal. Proc Natl Acad Sci. 2005;102(7): 2537-2542.
• 38. Sanchis-Gomar F, Lippi G, Mayero S, Perez-Quilis C, García-Giménez JL. Irisin: a new potential hormonal target for the treatment of obesity and type 2 diabetes. J Diabetes. 2012;4(3):196-196.
• 39. Ogawa A, Harris V, McCorkle SK, Unger RH, Luskey KL. Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment. J Clin Invest. 1990;85(3):973-976.
• 40. Boccia L, Gamakharia S, Coester B, Whiting L, Lutz TA, Le Foll C. Amylin brain circuitry. Peptides 2020; 132:170366.
• 41. Qiu WQ, Zhu H. Amylin and its analogs: a friend or foe for the treatment of Alzheimer’s disease? Front Aging Neurosci. 2014;6:186.
• 42. Babak D, Nicholas RSS, Carel WR. Amylin as a future obesity treatment. J Obes Metab Syndr. 2021;30(4): 320-325.
• 43. Zhang JV, Ren PG, Avsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin’s effects on food intake. Science. 2005; 310(5750):996-999.
• 44. Ren AJ, Guo ZF, Wang YK, et al. Inhibitory effect of obestatin on glucose-induced insulin secretion in rats. Biochem Biophys Res Commun. 2008;369(3):969-972.
• 45. Furnes WM, Stenstro¨m B, Tømmera˚ s K, et al. Feeding behaviour in rats subjected to gastrectomy or gastric bypass surgery. Eur Surg Res. 2008;40(3):279-288.
• 46. Lagaud GJ, Young A, Acena A, Morton MF, Barrett TD, Shankley NP. Obestatin reduces food intake and suppresses body weight gain in rodents. Biochem Biophys Res Commun. 2007;357(1):264-269.
• 47. Sibilia V, Bresciani E, Lattuada N, et al. Intracerebroventricular acute and chronic administration of obestatin minimally affect food intake but not weight gain in the rat. J Endocrinol Invest. 2006;29:31-34.
• 48. Yang GY, Li L, Chen WW, Liu H, Boden G, Li K. Circulating preptin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Ann Med. 2009;41(1):52-56.
• 49. Cheng KC, Li YX, Asakawa A, et al. Characterization of preptin-induced insulin secretion in pancreatic-cells. J Endocrinol. 2012;215(1):43-49.
• 50. Aslan M, Celik O, Karsavuran N, et al. Maternal serum, and cord blood preptin levels in gestational diabetes mellitus. J Perinatol. 2011;31(5):350-355.